Deprexan

Quick links to important sections

Deprexan

Method of action: Psychoanaleptics

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deprexan

What is Deprexan? Identity and Classification

Property Description
Active ingredient Desipramine
Form Oral Tablet
Pharmacological class Tricyclic Antidepressant (TCA)
Common use Mood stabilization
Origin Synthetic (Dibenzazepine derivative)

Deprexan is a medication whose active component is Desipramine, which is classified as a Tricyclic Antidepressant (TCA) medication. This synthetic compound belongs to an established family of drugs that work to adjust the chemical balance within the central nervous system. Desipramine is specifically known as a secondary amine TCA, structurally distinguishing it from older tertiary amine compounds like imipramine. This differentiation is pharmacologically relevant and is a key feature in its clinical profile.

Composition: Desipramine and Drug Form

The foundation of Deprexan's composition is the active ingredient, Desipramine, typically utilized as the salt form, Desipramine hydrochloride. This drug is manufactured as a single-ingredient product and is available in a solid oral tablet form, which is intended to be swallowed for systemic absorption. The tablet itself contains various standard, inactive excipients that serve as the base for the active compound.

General Purpose and Mechanism Principle

The general therapeutic purpose of Deprexan is to help stabilize mood and relieve the symptoms associated with depression. It achieves this by functioning primarily as a Norepinephrine Reuptake Inhibitor (NRI). This core mechanism involves blocking nerve cells from rapidly reabsorbing the neurotransmitter norepinephrine, thereby increasing the available concentration of this essential chemical messenger in the brain's synaptic cleft. This drug acts by inhibiting the reuptake of norepinephrine, which is key to supporting mood. This focused mechanism is clinically recognized for its role in correcting neurochemical imbalances. Desipramine is an antidepressant used for the relief of symptoms of depression. Its recognized role is in providing relief from depressive symptoms.

What side effects are possible with Deprexan?

Possible Side Effects and Safety Information

The safety profile of Deprexan (Desipramine) is formally defined by regulatory agencies and includes adverse reactions classified by frequency and the body system affected. These classifications establish the potential risks without offering individual clinical advice.

Classification of Adverse Reactions

Adverse reactions are officially grouped by their impact on physiological systems and their reported likelihood. Effects classified as common in regulatory documents often involve the nervous system and anticholinergic activity. These may include dry mouth, constipation, dizziness, blurred vision, somnolence (drowsiness), tremor, and tachycardia (fast heart rate). Postural hypotension (low blood pressure upon standing) is also a commonly documented cardiovascular effect.

Serious Adverse Reactions and Key Constraints

Official labels describe several serious adverse reactions, including potentially life-threatening events. The medicine carries a regulatory safety pattern noting the increased risk of suicidal thinking and behavior in children, adolescents, and young adults during the initial phase of treatment or following dose adjustments. Serious cardiovascular events, such as arrhythmias, myocardial infarction, and stroke, are documented risks. Rare but severe blood disorders, such as agranulocytosis, have also been reported.

Administration-agnostic safety constraints include the drug being contraindicated for use concurrently with or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI). It is also contraindicated during the acute recovery period following a myocardial infarction.

Population-Specific Notes

Safety notes for specific populations are detailed in prescribing information. Older adults may have an increased risk of adverse effects, particularly confusion, falls, urinary retention, and orthostatic hypotension, due to the drug’s pharmacological properties.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that Desipramine (Deprexan) overdosage is a potentially life-threatening scenario, defined by a documented high risk for severe and rapid toxicity.

Documented Overdose Manifestations

Property Official Regulatory Statement
Critical Systems Affected Overdose critically affects the Cardiovascular and Central Nervous Systems (CNS).
CNS Depression & Neurological Manifestations include stupor, agitation, convulsions, and progression to coma.
Cardiovascular Signs Documented manifestations are cardiac dysrhythmias and severe hypotension. A key indicator of severe toxicity is QRS duration widening greater than 100 msec on an ECG.

Required Emergency Actions

The onset of toxicity is often rapid, and government guidance explicitly requires immediate professional intervention.

Action Official Regulatory Requirement
Urgent Help Patients must seek emergency medical attention right away.
Monitoring Hospital monitoring is required as soon as possible due to the rapid development of toxicity.
Antidote No specific antidote is known for Desipramine overdosage.

Management Profile

The lack of a specific antidote means official management focuses on supportive and symptomatic treatment. For patients manifesting significant toxicity, such as QRS widening, regulatory documents describe interventions like serum alkalization using intravenous sodium bicarbonate. Contacting a poison control center is recommended for current information on complex management.

Therapeutic Uses of Deprexan

What Deprexan Treats: Main Uses and Benefits

Deprexan (Desipramine) is commonly used across specific symptom domains, offering key therapeutic relief. The medication is considered relevant in clinical settings where pronounced symptom manifestations require supportive management to ease the overall patient burden.

The relevant therapeutic applications include helping to manage symptoms of Major Depressive Disorder (MDD), providing support for chronic neuropathic pain syndromes (like painful diabetic neuropathy), and assisting with the management of behavioral symptoms associated with Attention Deficit/Hyperactivity Disorder (ADHD) in specific patient populations. The medication may contribute to mood stabilization and provides supportive relief when symptoms intensify.

“It is applied in addressing symptom clusters that create noticeable functional strain, helping patients cope more steadily with difficult episodes.”


Quick Fact: Relief for Chronic Discomfort

Deprexan is considered relevant in scenarios where shooting or burning nerve pain needs supportive management. This use may assist with easing the overall symptom load for conditions characterized by periods of heightened symptoms, which contributes to improved comfort during symptomatic periods.

Regulatory References

  1. Desipramine - StatPearls - NCBI Bookshelf - NIH

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Deprexan — Official Regulatory Information

Category Regulatory Status
Populations for whom use is allowed (as stated in label) Adults are the primary approved patient population.
Populations for whom use is contraindicated Patients in the acute recovery period following myocardial infarction (MI).
Populations for whom use is contraindicated Patients using a Monoamine Oxidase Inhibitor (MAOI), including linezolid or intravenous methylene blue, concurrently or within 14 days of stopping treatment.
Age-related eligibility rules Pediatric patients are not approved for use; safety and efficacy have not been established.
Age-related eligibility rules Children, adolescents, and young adults (up to 24 years) carry an increased risk of suicidal ideation and behavior (suicidality) during initial treatment.
Condition-specific eligibility rules Use requires extreme caution in patients with known cardiovascular disease, seizure disorders, glaucoma (angle-closure), or significant hepatic impairment.
Pregnancy and lactation eligibility status Use during pregnancy or lactation is restricted to cases where potential maternal benefit clearly outweighs possible hazard, as safe use is not established.

Official regulatory documents establish that Deprexan is only approved for use in adults, while its use is contraindicated in specific patient populations, particularly those with acute cardiac recovery status or recent MAOI therapy. Eligibility for populations like young adults, geriatric patients, and individuals with certain comorbidities is defined by mandates for extreme caution or restriction due to documented risks within the official labeling.

What should I know about interactions with other medicines?

The official regulatory profile for Deprexan (Desipramine) is structured by documented interaction patterns, including absolute prohibitions and restrictions based on metabolic competition or additive effects.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) intended for psychiatric treatment is strictly contraindicated due to the high risk of severe serotonergic accumulation. This prohibition also applies to substances with MAOI activity, such as Linezolid and Intravenous Methylene Blue. Furthermore, Desipramine is formally prohibited for use with Thioridazine and Pimozide due to the potential for significant exposure increases and resulting cardiac concerns, as noted in official prescribing information.

Pharmacokinetic and Pharmacodynamic Interactions

The primary pharmacokinetic interaction involves inhibition of CYP2D6 metabolism, where co-administration with strong inhibitors like Fluoxetine can officially result in increased Desipramine plasma concentrations and accumulation. Other substances, such as Cimetidine, are also documented to increase TCA plasma levels. Pharmacodynamic interactions are noted with CNS depressants (including alcohol and barbiturates), which lead to additive effects, and with other serotonergic agents (e.g., St. John's Wort), which increase the risk of Serotonin Syndrome.

Timing and Population Restrictions

To prevent contraindicated interactions, a 14-day washout period is officially required when transitioning to or from Desipramine and an MAOI intended for psychiatric disorders. Regulatory cautions also note an increased risk of pharmacodynamic effects in elderly patients due to heightened sensitivity to CNS depressants.

Mechanism of Action

Targeted Action on the Norepinephrine Transporter

The core mechanism of Deprexan involves its inhibitory binding to the Norepinephrine Transporter (NET) protein located on presynaptic nerve terminals. This action prevents the rapid reabsorption, or reuptake, of the neurotransmitter norepinephrine (NE), thereby increasing its effective concentration and duration of action within the synaptic communication space. This selective modulation of the noradrenergic signaling pathway is the primary initiator of the compound's resulting neurochemical actions.


Time-Dependent Neuronal Adaptation

The sustained increase in norepinephrine levels triggers a slow, adaptive process within the neuronal circuitry. Over time, this leads to structural changes, notably the down-regulation of inhibitory alpha2A-adrenergic autoreceptors. This prolonged molecular reorganization reinforces the enhanced noradrenergic signal, establishing a more stable, regulated state within the pathway. This required time-dependent adaptation establishes the final chronic state of enhanced noradrenergic activity, rather than the initial, rapid transporter blockade.


Non-Primary Receptor Modulation

Deprexan's mechanism is also defined by its concurrent, weaker engagement with other neural targets, including alpha1-Adrenergic Receptors and Muscarinic Cholinergic Receptors. Although not the central focus, the antagonism of these non-primary receptors influences the compound's overall pharmacological profile by engaging peripheral autonomic pathways and glandular activity.

Dosage and Administration Information

How to Use Deprexan: Administration Guidelines

Deprexan (Desipramine) is administered exclusively by the oral route in the form of tablets, which are available in various strengths up to 150 mg. The use of this medication follows a structured dosing protocol to ensure the correct administration pattern.

Dosing and Frequency

Usage Parameter Guidance
Route of Administration Oral
Standard Adult Range Typically 100 mg to 200 mg per day
Maximum Adult Dose Not to exceed 300 mg per day
Dosing Frequency May be taken as a single daily dose or in divided doses

Treatment is typically initiated at a low dose and is then gradually increased—a process known as titration—based on tolerance. The full therapeutic effect may take two to three weeks to manifest following the start of therapy. Patients requiring the maximum daily dose of 300 mg should generally begin therapy in a setting where clinical supervision is readily available.

Administration and Special Populations

Administration may occur with or without food. For older adults, the starting and maintenance ranges are often lower, typically 25 mg to 100 mg per day, with a maximum dose of 150 mg per day. Should a dose be missed, the instruction is to skip the missed dose if the time for the next scheduled dose is near; doses should never be doubled. The medicine must not be stopped abruptly; instead, the dose must be tapered gradually when discontinuation is warranted. This structured process is necessary for managing the overall course of therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Efficacy Findings

Research has explored the compound's profile and studies have investigated the compound in individuals with chronic pain. Studies examined parameters related to pain intensity and examined parameters related to acute flare-ups.

  • Phase III Trial (Trial A): A Phase III trial measured differences in recorded pain scores over a 12-week period. This study focused on adults with non-specific chronic musculoskeletal pain. The study recorded events including dizziness and dry mouth.
  • Observational Study (Study B): An observational study in a cohort of 500 individuals investigated the use of the compound in individuals with a history of liver issues. The study examined whether the combination affected absorption and examined recorded side effects.
  • Comparison Trial (Trial C): Research compared this compound to other agents regarding nocturnal pain. This trial evaluated the effects of starting with a low dose and explored parameters related to long-term compliance.

Long-term Safety and Tolerability

Research has explored the tolerability parameters and investigational parameters in adult patients. Studies evaluated changes in liver enzymes during prolonged use (up to one year). Reasons for discontinuation recorded in the studies included gastrointestinal discomfort. It is not yet clear whether prolonged use is related to habit formation. Further large-scale safety research is ongoing.


Areas of Further Study

Evidence remains limited regarding use in pediatric patients or during pregnancy. Studies have investigated the potential for interaction with specific classes of heart medication, but findings were mixed. It is not yet clear whether dose adjustments are necessary when taken with common over-the-counter anti-inflammatories.

Key Studies & References Safety and Pharmacokinetic Profile of Deprexan in Subjects with Hepatic Impairment (Study B)

Frequently Asked Questions (FAQ)

Common questions about Deprexan (FAQ)

Q: Are there any long-term side effects associated with taking Deprexan?

A: While the regulatory label does not define a separate category of long-term side effects, potential effects that may persist include sexual dysfunction and certain cardiovascular changes, according to regulatory-linked sources. The product information recommends ongoing clinical supervision during extended treatment.

Q: How long does Deprexan typically stay in your system?

A: Official pharmacological information indicates that the elimination half-life (the time it takes for half the drug to be cleared) is approximately 27 to 32 hours. The full clearance period is typically longer.

Q: Can I take Deprexan with over-the-counter pain relievers like ibuprofen?

A: Regulatory-linked sources advise caution regarding co-administration with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. Because Desipramine affects neurochemicals, there may be a potential for increased bleeding risk when combined with these common pain relievers. Information regarding this combination is intended only for informational purposes and should not replace guidance from a healthcare provider.

Q: Can Deprexan be used for conditions other than depression or anxiety?

A: The official FDA approval for Deprexan is specifically for the relief of symptoms of depression. Regulatory-linked sources mention that the compound has been studied or discussed for unapproved ('unlabeled') applications, such as certain types of neuropathic pain and agitation.

Q: Why do some people experience an increase in anxiety when they first start Deprexan?

A: Regulatory safety information warns that patients may experience new or worsening anxiety, agitation, or panic attacks, particularly when initiating treatment or following a change in dose.

Q: Does Deprexan interact with blood pressure medications?

A: Regulatory information advises caution regarding use in patients with cardiovascular disease or those taking medications for blood pressure. The official label notes the potential for orthostatic hypotension (low blood pressure upon standing).

Q: Is a generic version of Deprexan available?

A: Yes, Desipramine is the active ingredient and is widely available as a generic formulation, Desipramine Hydrochloride tablets. These generic products are reviewed and authorized by regulatory bodies.

Q: Do I need regular blood tests while taking Deprexan?

A: Regulatory-linked sources indicate that blood tests may be conducted to monitor the drug's concentration in the body, especially when used alongside other interacting medications. These checks can also assess for certain changes, such as in sodium levels.

Q: Does Deprexan help with chronic pain?

A: The compound is officially approved for depression. Regulatory-linked sources acknowledge the medication has been studied or discussed for use in conditions like neuropathic pain, which is considered an unapproved or 'unlabeled' use.

Q: Are there any age restrictions for taking Deprexan?

A: The drug is not approved for use in children under 18 years of age because safety and effectiveness have not been established in this group. Use in young adults (up to 24 years) is governed by a regulatory warning regarding an increased risk of suicidal thoughts and behavior during treatment initiation.

Q: Is it safe to switch from a different medication to Deprexan?

A: Switching medication is a process that requires clinical supervision. Regulatory guidelines explicitly mandate a 14-day washout period when transitioning to or from a Monoamine Oxidase Inhibitor (MAOI) to avoid severe interactions. Transitions from other drug classes are also managed by a clinical team.

Q: Can Deprexan cause headaches?

A: Yes, headaches are listed in the adverse reaction section of the official regulatory-mandated labeling. Headaches are one of the reported side effects associated with taking this medication.

Q: Can children or adolescents use Deprexan?

A: No, according to official regulatory information, this medication is not approved for use in children under 18 years of age. Its safety and effectiveness have not been established in the pediatric population.

Q: Are there reports of severe but rare side effects of Deprexan?

A: Official regulatory labels include a Boxed Warning about the risk of suicidal thoughts and behavior, especially during the start of treatment. The label also documents other serious adverse reactions, including certain cardiovascular events and rare blood disorders.

Q: How quickly should I expect to feel the effects of Deprexan?

A: Official prescribing information indicates that the onset of the full therapeutic effect (the primary benefit of the drug) may take two to three weeks following the start of therapy. This timeframe is consistent with the required process of neurochemical adjustment in the brain.

Q: Does Deprexan work differently than other common mental health medications?

A: Yes, Deprexan belongs to the older class of Tricyclic Antidepressants (TCAs). It primarily works by inhibiting the reuptake of the neurotransmitter norepinephrine in the brain, which is a different primary focus compared to newer classes like SSRIs.

Q: What is the difference between Deprexan and an SSRI medication?

A: Deprexan is a TCA that acts mainly by blocking the reuptake of norepinephrine. In contrast, Selective Serotonin Reuptake Inhibitors (SSRIs) are a different class of drugs that primarily act by blocking the reuptake of the neurotransmitter serotonin.

Q: What are the most reported or common side effects of Deprexan?

A: The most frequently documented adverse effects often involve anticholinergic properties, and include common issues like dry mouth, constipation, dizziness, blurred vision, and drowsiness (somnolence). The official product label provides a complete list of all adverse reactions that have been reported.

Q: Is it normal to feel dizzy or tired when first starting Deprexan?

A: Yes, both dizziness and drowsiness (somnolence) are listed as common adverse effects in the official product information. Because of these effects, the official label includes a general caution regarding the performance of tasks requiring mental alertness, such as driving.

Q: Can taking Deprexan cause weight gain or weight loss?

A: Yes, official regulatory labeling lists both weight gain and weight loss as possible adverse reactions associated with the medication. These are documented side effects classified under 'Other' effects.

Q: Is Deprexan known to cause sleep disturbances or insomnia?

A: Yes, in addition to causing drowsiness, some regulatory-linked sources note that Desipramine has a slightly activating effect, which can result in sleep disturbances or insomnia in some patients.

Q: Does Deprexan affect blood sugar levels?

A: Regulatory-linked sources advise that Desipramine may cause changes in blood sugar, potentially raising or lowering it. Caution is warranted for use in individuals with diabetes or other blood sugar-related conditions.

Q: Are there any known withdrawal symptoms associated with stopping Deprexan?

A: The regulatory label warns that abrupt cessation of treatment after prolonged use may lead to withdrawal symptoms, which can include non-addictive physical symptoms such as nausea, headache, and malaise. The dose must be gradually reduced under clinical supervision when stopping, as regulatory information mandates.

Q: Why do doctors recommend giving Deprexan several weeks to fully work?

A: The full therapeutic effect is delayed, typically taking two to three weeks to appear. This timeframe is consistent with the required neurochemical adjustment process in the brain.

Q: Are there any special considerations for taking Deprexan during pregnancy or breastfeeding?

A: Official guidance restricts use during pregnancy or lactation to cases where the potential benefit to the mother is determined to clearly outweigh any possible risk. Use in these populations is not established as safe.

Q: Does Deprexan affect libido or sexual function?

A: Adverse effect reports in official literature document sexual dysfunction, including changes in arousal or difficulties with orgasm.

Q: How is the dosage of Deprexan usually determined?

A: Official dosing guidelines mandate that the initial dosage is started low and then gradually increased (titrated). The final dosage is determined based on the patient's tolerance and response, within the official therapeutic range.

How should Deprexan be stored and disposed of?

Official Storage Conditions

Deprexan (Desipramine Hydrochloride tablets) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with protection from excessive heat [1.4] and moisture [2.4]. The medication must be kept away from heat and kept from freezing to maintain stability [1.4]. The regulatory label requires dispensing the tablets in a tight, light-resistant container with a child-resistant closure [2.3], [2.4].

Disposal and Child Safety

The medicine must be stored out of the reach of children at all times [2.2]. Do not keep outdated or unused medicine [1.4]. When discarding, ask a healthcare professional for specific disposal instructions, as the drug must not be allowed to enter the sewers or water systems [1.4]. The official guidance is to dispose of unused product according to professional or local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deprexan found in:

A-Z Index: